SphingoTec develops and markets innovative IVD solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice.
Our innovative biomarkers address diagnostically underserved acute and critical care conditions such as acute kidney injury, sepsis, and acute heart failure. The solutions we have created combine scientific discoveries with medical research and robust technologies to support clinicians in improving patient care. We work with internationally leading academic and non-academic medical centers as well as global IVD and pharma companies to bring these innovations closer to the patients.
Innovative diagnostic solutions for unmet medical needs
We collaborate with a wide range of industry partners to convey the value of our biomarker innovations in clinical diagnostics and drug development.
A new, improved formula has been developed for estimating the GFR using kidney function biomarker penKid. According to the data, penKid strongly correlates with the measured GFR (mGFR), while the penKid-based formula for estimating GFR performs better than routinely used equations.
A new study and real-world data on the kidney function biomarker penKid underline its potential to monitor kidney function during acute kidney injury (AKI) and RRT and to support liberation decisions from RRT.
The Symposium on Intensive Medicine and Intensive Care is a platform for professionals in the field to discuss current scientific findings, clinical developments, and standards in anesthesiology, intensive medicine, and intensive care.